查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1598431

血栓症藥物市場：按藥物類別、疾病類型、分銷管道分類 - 全球預測 2025-2030

Thrombosis Drug Market by Drug Class (Factor Xa Inhibitor, Heparin, P2Y12 Platelet Inhibitor), Disease Type (Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism), Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年血栓症治療市值為289.3億美元，預計到2024年將達到306億美元，複合年成長率為5.84%，到2030年將達到430.6億美元。

血栓症藥物市場包括用於預防和治療血管血栓的藥物，這些血栓會導致深層靜脈栓塞症（DVT）、肺動脈栓塞（PE）和中風等疾病。血栓症藥物在臨床上極為重要，特別是對於接受手術的患者、心房顫動患者以及血栓形成高風險的患者。應用範圍跨越醫院、專科診所、居家照護等多種醫療環境，最終使用者為醫療保健專業人員和患者。市場成長主要是由於心血管疾病盛行率的增加、人口老化以及對血栓症疾病認知的提高而推動的。此外，口服抗凝血劑和標靶治療等藥物傳遞系統的進步也是主要的成長要素。個人化醫療方法和生技藥品存在新的商機，可以有效減少副作用並改善治療結果。然而，市場擴張受到嚴格法律規範、高昂開發成本以及阻礙藥品核准和定價的專利懸崖等因素的阻礙。此外，與抗凝血劑相關的併發症（例如出血風險）也是局限性的。儘管存在這些挑戰，市場仍然存在巨大的創新潛力，包括開發更安全的下一代抗凝血劑以及整合人工智慧主導的診斷以更好地進行患者分層等。您可以利用全面的患者資料來提供真實世界的證據，並透過快速成長的醫療基礎設施進入開拓的市場，從而推動成長。與生技公司的合作以及針對新藥機制的研發投資也將在克服市場障礙方面發揮關鍵作用。整體而言，血栓症藥物市場充滿活力，在更安全、更有效的治療選擇方面還有很大的研發空間。

主要市場統計
基準年[2023] 289.3億美元
預測年份 [2024] 306億美元
預測年份 [2030] 430.6億美元
複合年成長率（%） 5.84%

市場動態：揭示快速發展的血栓症藥物市場的關鍵市場洞察

供需的動態交互作用正在改變血栓症藥物市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 提高患者對血栓症治療的認知
    • 腎臟疾病、中風和高血壓的盛行率飆升
    • 有利的藥品報銷方案
  • 市場限制因素
    • 藥物和治療費用上漲
  • 市場機會
    • 治療技術的進步和零售藥局的增加
    • 增加醫療支出和增加協作活動
  • 市場挑戰
    • 嚴格的藥品監管體系

波特五力：駕馭血栓症藥物市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢、解決弱點並避免潛在的挑戰，以確保更強大的市場地位。

PESTLE分析：了解血栓症藥物市場的外部影響

外部宏觀環境因素對血栓症治療藥物市場的表現動態起著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解血栓症治療藥物市場競爭狀況

對血栓症治療藥物市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位基質血栓症治療市場供應商的績效評估

FPNV定位矩陣是評估血栓症治療市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，繪製血栓症治療市場的成功之路

對於旨在加強在全球市場的影響力的公司來說，對血栓症治療藥物市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監管核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 提高患者對血栓症治療的認知
      • 腎臟疾病、中風和高血壓的發生率飆升
      • 有利的藥品報銷方案
    • 抑制因素
      • 藥物和治療費用高昂
    • 機會
      • 治療技術進步與零售藥局的興起
      • 醫療費用增加和關節活動增加
    • 任務
      • 嚴格的藥品管制制度
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章依藥物類別血栓症藥物市場

  • Xa因子抑制劑
  • 肝素
  • P2Y12血小板抑制劑

第7章血栓症治療藥物市場：依疾病類型

  • 心房顫動
  • 深層靜脈栓塞症
  • 肺動脈栓塞

第8章血栓症治療藥物市場：按分銷管道

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第9章北美和南美血栓症治療市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太地區血栓症治療市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章歐洲、中東和非洲血栓症治療藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Aspen Pharmacare Holdings Limited by Mylan NV
  • Aurobindo Pharmaceuticals USA, Inc.
  • B. Braun Melsungen AG
  • Bayer AG
  • Becton, Dickinson and Company
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb
  • Cardinal Health, Inc.
  • GoodRx Holdings, Inc.
  • Grifols, SA
  • Inari Medical, Inc.
  • ITALFARMACO SpA
  • Johnson & Johnson Services, Inc.
  • Pfizer, Inc
  • Sanofi SA
Product Code: MRR-030298DFFFC8

The Thrombosis Drug Market was valued at USD 28.93 billion in 2023, expected to reach USD 30.60 billion in 2024, and is projected to grow at a CAGR of 5.84%, to USD 43.06 billion by 2030.

The thrombosis drug market encompasses medications used for the prevention and treatment of blood clots within blood vessels, which can lead to conditions such as deep vein thrombosis (DVT), pulmonary embolism (PE), and strokes. Thrombosis drugs are crucial in clinical settings, especially for patients undergoing surgeries, with atrial fibrillation, or those at high risk of clot formation. The application scope spans multiple healthcare settings, including hospitals, specialized clinics, and homecare settings, with end-users comprising healthcare professionals and patients. The market's growth is primarily driven by the increasing prevalence of cardiovascular diseases, an aging population, and heightened awareness of thrombosis disorders. Additionally, advancements in drug delivery systems, such as oral anticoagulants and targeted therapies, are significant growth influencers. Emerging opportunities lie in personalized medicine approaches and innovations in biologics, effectively reducing side effects and enhancing therapeutic outcomes. However, market expansion is hindered by factors such as stringent regulatory frameworks, high developmental costs, and patent cliffs challenging drug approvals and pricing. Furthermore, complications such as bleeding risks associated with anticoagulants pose limitations. Despite these challenges, the market offers substantial potential for innovation, particularly in developing safer, next-generation anticoagulants and integrating AI-driven diagnostics for better patient stratification. Leveraging comprehensive patient data to inform real-world evidence and expanding into underserved markets with burgeoning healthcare infrastructure can bolster growth. Collaborations with biotechnology firms and investments in R&D focusing on novel drug mechanisms can also play crucial roles in overcoming market barriers. Overall, the thrombosis drugs market is dynamic, with enormous scope for research and development directed toward safer and more effective therapeutic options.

KEY MARKET STATISTICS
Base Year [2023] USD 28.93 billion
Estimated Year [2024] USD 30.60 billion
Forecast Year [2030] USD 43.06 billion
CAGR (%) 5.84%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Thrombosis Drug Market

The Thrombosis Drug Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing patient awareness regarding thrombosis treatment
    • Surge in prevalence of kidney diseases, stroke, and hypertension
    • Favorable reimbursement scenario for the drugs
  • Market Restraints
    • High cost of the medicines and treatment
  • Market Opportunities
    • Technological advancements in the treatment and increasing number of retail pharmacies
    • Growing healthcare expenditure and rise of collaborative activities
  • Market Challenges
    • Strict drug regulatory systems

Porter's Five Forces: A Strategic Tool for Navigating the Thrombosis Drug Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Thrombosis Drug Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Thrombosis Drug Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Thrombosis Drug Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Thrombosis Drug Market

A detailed market share analysis in the Thrombosis Drug Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Thrombosis Drug Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Thrombosis Drug Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Thrombosis Drug Market

A strategic analysis of the Thrombosis Drug Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Thrombosis Drug Market, highlighting leading vendors and their innovative profiles. These include Aspen Pharmacare Holdings Limited by Mylan N.V., Aurobindo Pharmaceuticals USA, Inc., B. Braun Melsungen AG, Bayer AG, Becton, Dickinson and Company, Boehringer Ingelheim GmbH, Bristol-Myers Squibb, Cardinal Health, Inc., GoodRx Holdings, Inc., Grifols, S.A, Inari Medical, Inc., ITALFARMACO S.p.A, Johnson & Johnson Services, Inc., Pfizer, Inc, and Sanofi S.A..

Market Segmentation & Coverage

This research report categorizes the Thrombosis Drug Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Class, market is studied across Factor Xa Inhibitor, Heparin, and P2Y12 Platelet Inhibitor.
  • Based on Disease Type, market is studied across Atrial Fibrillation, Deep Vein Thrombosis, and Pulmonary Embolism.
  • Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing patient awareness regarding thrombosis treatment
      • 5.1.1.2. Surge in prevalence of kidney diseases, stroke, and hypertension
      • 5.1.1.3. Favorable reimbursement scenario for the drugs
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of the medicines and treatment
    • 5.1.3. Opportunities
      • 5.1.3.1. Technological advancements in the treatment and increasing number of retail pharmacies
      • 5.1.3.2. Growing healthcare expenditure and rise of collaborative activities
    • 5.1.4. Challenges
      • 5.1.4.1. Strict drug regulatory systems
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Thrombosis Drug Market, by Drug Class

  • 6.1. Introduction
  • 6.2. Factor Xa Inhibitor
  • 6.3. Heparin
  • 6.4. P2Y12 Platelet Inhibitor

7. Thrombosis Drug Market, by Disease Type

  • 7.1. Introduction
  • 7.2. Atrial Fibrillation
  • 7.3. Deep Vein Thrombosis
  • 7.4. Pulmonary Embolism

8. Thrombosis Drug Market, by Distribution Channel

  • 8.1. Introduction
  • 8.2. Hospital Pharmacies
  • 8.3. Online Pharmacies
  • 8.4. Retail Pharmacies

9. Americas Thrombosis Drug Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Thrombosis Drug Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Thrombosis Drug Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Aspen Pharmacare Holdings Limited by Mylan N.V.
  • 2. Aurobindo Pharmaceuticals USA, Inc.
  • 3. B. Braun Melsungen AG
  • 4. Bayer AG
  • 5. Becton, Dickinson and Company
  • 6. Boehringer Ingelheim GmbH
  • 7. Bristol-Myers Squibb
  • 8. Cardinal Health, Inc.
  • 9. GoodRx Holdings, Inc.
  • 10. Grifols, S.A
  • 11. Inari Medical, Inc.
  • 12. ITALFARMACO S.p.A
  • 13. Johnson & Johnson Services, Inc.
  • 14. Pfizer, Inc
  • 15. Sanofi S.A.

LIST OF FIGURES

  • FIGURE 1. THROMBOSIS DRUG MARKET RESEARCH PROCESS
  • FIGURE 2. THROMBOSIS DRUG MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL THROMBOSIS DRUG MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS THROMBOSIS DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS THROMBOSIS DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES THROMBOSIS DRUG MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES THROMBOSIS DRUG MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC THROMBOSIS DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC THROMBOSIS DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA THROMBOSIS DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA THROMBOSIS DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. THROMBOSIS DRUG MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. THROMBOSIS DRUG MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. THROMBOSIS DRUG MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL THROMBOSIS DRUG MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. THROMBOSIS DRUG MARKET DYNAMICS
  • TABLE 7. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY FACTOR XA INHIBITOR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY HEPARIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY P2Y12 PLATELET INHIBITOR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY ATRIAL FIBRILLATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY DEEP VEIN THROMBOSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY PULMONARY EMBOLISM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS THROMBOSIS DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 32. MEXICO THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES THROMBOSIS DRUG MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC THROMBOSIS DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 43. AUSTRALIA THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 46. CHINA THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 49. INDIA THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 52. INDONESIA THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 55. JAPAN THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 58. MALAYSIA THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 61. PHILIPPINES THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 64. SINGAPORE THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 67. SOUTH KOREA THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 70. TAIWAN THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 73. THAILAND THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 76. VIETNAM THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA THROMBOSIS DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 83. DENMARK THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 86. EGYPT THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 89. FINLAND THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 92. FRANCE THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 95. GERMANY THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 98. ISRAEL THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 101. ITALY THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 104. NETHERLANDS THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 107. NIGERIA THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 110. NORWAY THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 113. POLAND THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 116. QATAR THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 119. RUSSIA THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 122. SAUDI ARABIA THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH AFRICA THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 128. SPAIN THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 131. SWEDEN THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 134. SWITZERLAND THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 137. TURKEY THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED ARAB EMIRATES THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED KINGDOM THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 146. THROMBOSIS DRUG MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 147. THROMBOSIS DRUG MARKET, FPNV POSITIONING MATRIX, 2023